ECE2021 Audio Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (223 abstracts)
Clinical research out of insulin glargine u300 in type 1 diabetes mellitus patients with frequent hypoglycemia: a real world experience
Savas Volkan Kisioglu 1 , 2 , Ahmet Suat Demir 2 , Damla Tufekci 3 , Yasemin Emur Gunay 2 , Hulya Coskun 2 , Ozge Ucuncu 2 , Irfan Nuhoglu 2 , Mustafa Kocak 2 , Serdar Karakullukcu 3 & Halil Onder Ersoz 2
1Health Sciences University Kanuni Training and Research Hospital, Department of Endocrinology; 2Karadeniz Technical University, Department of Endocrinology, trabzon, Turkey; 3Bayburt Community Health Center, Community Health Center, Turkey
Aims/Introduction
We aimed to see whether Insulin Glargine U300 can provide better blood glucose control while reducing hypoglycemia in a more homogeneous population compared to previous studies.
Materials and methods
For evaluation of FBG, HbA1c and weight at 6 months and all variables final, observation windows of 120–240 days (4–8 months) and 240–480 days (9–16 months) after Insulin Glargine U300 initiation, respectively, were permitted. Hypoglycemia was defined as blood glucose level < 70 mg/dl, either symptomatic or asymptomatic, or measured in hospital or at home.
Results
The 35 patients comprised, 20 (57.1%) female and 15 (42.9%) men with a mean age of 24.1 ± 6.6 years. Mean BMI was 24.4 ± 7.4 kg/m2. Pre-study treatment regimens were given Table 1. A significant decrease was not found between baseline and HbA1C values in 6 month (P = 0.199) but in follow-up period (between 9–16 month) significant decrease was found (P = 0.025) (Table 2.). Hypoglycemic events occurred in all patients (100%) before using Insulin Glargine U300, while the incidence of hypoglycemic events gradually decreased to 74.3%, 68.6% and 68.6% between months 1–3, 3–6 and 6–9 respectively. Of the 26 patients that declared their satisfaction, 23 (88.5%) of them were satisfied, 2 (7.7%) of them indicated that there was no significant difference, and 1 (3.8%) patient was unsatisfied.
Conclusions
Over 9 – 16 month follow up period, Insulin Glargine U300 led to a significant reduction not only in HbA1c levels but also in the frequency of hypoglycemia, and also yielded high satisfaction rates.
| Treatment | n (%) |
| Basal insulin + bolus insulin | 35 (100) |
| IGlar U100 | 28 (80) |
| Insulin Detemir | 7 (20) |
| Insulin Aspart | 23 (65.7) |
| Insulin Lispro | 8 (22.2) |
| Insulin Glulisin | 4 (11.1) |
| Means | P** | |
| Fasting blood glucose (mg/dl)† | ||
| Baseline – 6 month | 191.2 ± 114.3–180.8 ± 97.9 | 0.678 |
| Baseline – Final | 191.2 ± 114.3–149.5.3 ± 62.4 | 0.043 |
| 6 month – Final | 180.8 ± 97.9–149.5.3 ± 62.4 | 0.054 |
| HbA1c (%)†[mmol/mol] † | ||
| Baseline – 6 month | 9 ± 2[74.9 ± 21.9]–8.9 ± 2[73.8 ± 21.9] | 0.199 |
| Baseline – Final | 9 ± 2[74.9 ± 21.9]–8.7 ± 1.6[71.6 ± 17.5] | 0.025 |
| 6 month – Final | 8.9 ± 2[73.8 ± 21.9]–8.7 ± 1.6[71.6 ± 17.5] | 0.179 |
| Weight (kg) † | ||
| Baseline – 6 month | 66.3 ± 11.6–66.4 ± 12.1 | 0.835 |
| Baseline – Final | 66.3 ± 11.6–66.5 ± 12.8 | 0.796 |
| 6 month – Final | 66.4 ± 12.1–66.5 ± 12.8 | 0.811 |
| †: mean ± SD, **Paired t-test | ||
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more